<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vedomostiregmed</journal-id><journal-title-group><journal-title xml:lang="ru">Регуляторные исследования и экспертиза лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Regulatory Research and Medicine Evaluation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-3062</issn><issn pub-type="epub">3034-3453</issn><publisher><publisher-name>Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">vedomostiregmed-138</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Валидация методики определения аминокислотного состава фармацевтической субстанции «Глатирамера ацетат» методом13C ЯМР-спектроскопии</article-title><trans-title-group xml:lang="en"><trans-title>Validation of the procedure for determination of amino acids composition of glatiramer acetate by C-13 NMR spectroscopy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузьмина</surname><given-names>Н. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuz’Mina</surname><given-names>N. E.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Моисеев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Moiseev</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крылов</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Krylov</surname><given-names>V. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutin</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жуков</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhukov</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яшкир</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yashkir</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Меркулов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Merkulov</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НЦ экспертизы средств медицинского применения</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Scientific Centre for Expert Evaluation of Medicinal Products</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>13</day><month>02</month><year>2018</year></pub-date><volume>7</volume><issue>3</issue><fpage>175</fpage><lpage>181</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кузьмина Н.Е., Моисеев С.В., Крылов В.И., Кутин А.А., Жуков Е.А., Яшкир В.А., Меркулов В.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Кузьмина Н.Е., Моисеев С.В., Крылов В.И., Кутин А.А., Жуков Е.А., Яшкир В.А., Меркулов В.А.</copyright-holder><copyright-holder xml:lang="en">Kuz’Mina N.E., Moiseev S.V., Krylov V.I., Kutin A.A., Zhukov E.A., Yashkir V.A., Merkulov V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.vedomostincesmp.ru/jour/article/view/138">https://www.vedomostincesmp.ru/jour/article/view/138</self-uri><abstract><p>Описана процедура валидации методики определения аминокислотного состава фармацевтической субстанции «Глатирамера ацетат» методом13C ЯМР-спектроскопии, которая позволяет измерять мольное отношение аминокислот, входящих в состав глатирамера ацетата, без использования соответствующих стандартных образцов. Проведена оценка правильности, линейности, сходимости, внутрилабораторной прецизионности, и специфичности валидируемой методики. На основе измеренных коэффициентов «найдено : введено» для L-Glu, L-Ala, L-Tyr и L-Lys были рассчитаны систематические погрешности, стандартные отклонения, доверительные интервалы, коэффициенты вариации, F-критерии Фишера и t-критерии Стьюдента результатов измерения мольного отношения аминокислот. Показано, что полученные статистические характеристики удовлетворяют критериям приемлемости валидационных параметров, представленным в отечественной и зарубежной нормативной документации.</p></abstract><trans-abstract xml:lang="en"><p>The article describes validation of the procedure for determination of amino acids composition of glatiramer acetate by C-13 NMR spectroscopy. The procedure makes it possible to determine the molar ratio of amino acids present in glatiramer acetate with no need for a reference standard. The authors evaluated the accuracy, linearity, repeatability, intermediate precision and specificity of the validated procedure. The analysis of extraction factors for L-Glu, L-Ala, L-Tyr и L-Lys helped to calculate the systematic errors, standard deviations, confidence intervals, variation coefficients, confidence intervals, Fisher’s test and Student’s t-test for the results of amino acids molar ratio determination. It was shown that the obtained statistical data satisfy the acceptance criteria for validation parameters described in the national and foreign quality standards.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>глатирамера ацетат</kwd><kwd>метод13C ЯМР-спектроскопии</kwd><kwd>аминокислотный состав</kwd><kwd>валидация аналитической методики</kwd><kwd>линейность</kwd><kwd>правильность</kwd><kwd>сходимость</kwd><kwd>прецизионность</kwd><kwd>glatiramer acetate</kwd><kwd>C-13 NMR spectroscopy</kwd><kwd>amino acids composition</kwd><kwd>analytical procedure validation</kwd><kwd>linearity</kwd><kwd>accuracy</kwd><kwd>repeatability</kwd><kwd>precision</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Шмидт ТЕ. Глатирамера ацетат - препарат первого ряда с двойным действием для лечения ремиттирующего рассеянного склероза. Неврология, нейропсихиатрия, психосоматика 2016; 8(4): 77-80.</mixed-citation><mixed-citation xml:lang="en">Shmidt TE. Glatiramer acetate is a first-line dual-action drug for the treatment  of relapsing-remitting multiple sclerosis. Neurology, Neuropsychiatry, Psychosomatics 2016; 8(4): 77–80 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Кузьмина НЕ, Моисеев СВ, Крылов ВИ, Кутин АА, Яшкир ВА, Меркулов ВА. Разработка методики определения аминокислотного состава фармацевтической субстанции «Глатирамера ацетат» методом ЯМР-спектроскопии. Химико-фармацевтический журнал 2017; 51(3): 45-8.</mixed-citation><mixed-citation xml:lang="en">Kuz’mina NE, Moiseev SV, Krylov VI, Kutin AA, Yashkir VA, Merkulov VA.  Development of the procedure for determination of amino acids composition of  glatiramer acetate by NMR spectroscopy. Pharmaceutical Chemistry Journal 2017; 51(3); 45–8 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Кузьмина НЕ, Моисеев СВ, Яшкир ВА, Осинцева ЕВ. Возможности использования метода ЯМР при аттестации стандартных образцов. Стандартные образцы 2014; (2): 19-25.</mixed-citation><mixed-citation xml:lang="en">Kuz’mina NE, Moiseev SV, Yashkir VA, Osintseva EV. The possibility of the nuclear  magnetic resonance methods using for reference standards certification. Reference  materials 2014; (2): 19–25 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Malz F, Jancke H. Validation of quantitative nuclear magnetic resonance. J Pharm Biomed Anal. 2005; 38(5): 813-23.</mixed-citation><mixed-citation xml:lang="en">Malz F, Jancke H. Validation of quantitative nuclear magnetic resonance. J Pharm Biomed Anal. 2005; 38(5): 813–23.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Юргель НВ, ред. Руководство по валидации методик анализа лекарственных средств. Методические рекомендации. М.: Спорт и культура-2000; 2007.</mixed-citation><mixed-citation xml:lang="en">Yurgel NV, ed. Guideline for Analytical Methods Validation for Drugs.  Methodological Recommendations. Moscow: Sport i Kul’tura-2000; 2007 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Береговых ВВ, ред. Валидация аналитических методик для производителей лекарств. Типовое руководство предприятия по производству лекарственных средств М.: Литтерра; 2008.</mixed-citation><mixed-citation xml:lang="en">Beregovykh VV, ed. Validation of analytical methods by drug manufacturers. Guiding principles for drug manufacturers. Moscow: Litterra;  2008 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Общая фармакопейная статья 1.1.0012.15. Валидация аналитических методик. Государственная фармакопея Российской Федерации. XIII изд. Т. I. М.; 2015. Available from: http://femb.ru/ feml.</mixed-citation><mixed-citation xml:lang="en">General monograph 1.1.0012.15. Validation of analytical procedures. State  Pharmacopoeia of the Russian Federation. 13th ed. V. I. Moscow; 2015. Available from: http://femb.ru/feml (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nuclear Magnetic Resonance. United States Pharmacopoeia. National Formulary USP 40 - NF 35. Rockville; 2016.</mixed-citation><mixed-citation xml:lang="en">Nuclear Magnetic Resonance. United States Pharmacopoeia. National Formulary USP 40—NF 35. Rockville; 2016.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">РМГ 61-2003 ГСИ. Показатели точности, правильности, прецизионности методик количественного химического анализа. Методы оценки. М.: Издательство стандартов; 2004.</mixed-citation><mixed-citation xml:lang="en">RMG 61–2003 GSI. Accuracy, trueness and precision of quantitative chemical  analysis. Methods of evaluation. Moscow: Izdatelstvo standartov; 2004 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">ГОСТ Р ИСО 5725-2-2002. Точность (правильность и прецизионность) методов и результатов измерений. Ч. 2. Основной метод определения повторяемости и воспроизводимости стандартного метода измерений. М.: Издательство стандартов; 2002.</mixed-citation><mixed-citation xml:lang="en">State Standard R ISO 5725-2–2002. Accuracy (trueness and precision) of  measurement methods and results. Part 2. Basic method for determination of  repeatability and reproducibility of a standard method of measurement. Moscow: Izdatelstvo standartov; 2002 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Долитцки Б-З. Способ получения смесей полипептидов с использованием очищенной бромистоводородной кислоты. Патент Российской Федерации, № 2388764 С2; 2010.</mixed-citation><mixed-citation xml:lang="en">Dolittski B-Z. Method of preparation of polypeptide mixtures using purified  hydrobromic acid. Patent RF, ¹ 2388764 C2; 2010 (in Russian).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
